Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.82 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560908 | 1.00 | HDAC1 (0.82) | HDAC1HDAC8HDAC6ALDH1A1ESR1 | |
| SCHEMBL8249069 | 0.92 | HDAC1 (0.82) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5566198 | 0.91 | HDAC1 (0.70) | HDAC1HDAC8HDAC6ESR1ESR2 | |
| SCHEMBL5566196 | 0.91 | HDAC1 (0.70) | HDAC1HDAC8HDAC6ESR1ESR2 | |
| SCHEMBL5566274 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5566278 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL8243328 | 0.89 | HDAC1 (0.88) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5567187 | 0.87 | HDAC1 (0.81) | HDAC1HDAC8HDAC6ESR1ESR2 | |
| SCHEMBL5567183 | 0.87 | HDAC1 (0.81) | HDAC1HDAC8HDAC6ESR1ESR2 | |
| SCHEMBL5560952 | 0.87 | HDAC1 (0.64) | HDAC1HDAC8HDAC6ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | claimed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | claimed |
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004082638-A2 | HISTONE DEACETYLASE INHIBITORS | SYRRX, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266769-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | HDAC1 1/4885HDAC8 10/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.